Financings in Brief: Angeion
This article was originally published in The Gray Sheet
Executive Summary
Angeion: Files registration statement with Securities and Exchange Commission for a direct placement, principally to selected institutional investors, of 2.5 mil. shares of common stock. Proceeds will go toward R&D, clinical trials, capital equipment, leasehold improvements and general corporate purposes, the Minneapolis-based firm says. Stock in Angeion has recently been trading in the $4-6 range. The firm is developing the Sentinel implantable cardioverter defibrillator and catheter ablation systems. The offering follows a direct placement of 4.9 mil. securities last fall ("The Gray Sheet" Oct. 10, 1994, p. 20). Raymond James & Associates is placement agent for the offering...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.